AMRA Medical provides medical imaging services focusing on body composition analysis using MRI technology. The services include clinical and research applications to deliver precise body measurements, as self-described.

AMRA Medical

Gesund.ai empowers medical AI developers to establish, optimize, and sustain their AI lifecycles, ensuring privacy, compliance, speed, and scalability.

Gesund.ai

AMRA Medical | 3,317 followers on LinkedIn. Precision for Vital Medical Decisions | AMRA originated with precision medicine in mind, understanding that to effectively target our greatest global health challenges, we need a precise, cost-effective way to understand our bodies far beyond what is available today.

AMRA is a health informatics company at the forefront of medical imaging and precision medicine. The company has developed a new global standard in body composition assessment, the ability to automatically produce multiple fat and muscle biomarkers with unrivaled precision and accuracy, alongside contextual disease insights – all from a single, rapid, whole-body MRI.

Tommy Johansson

DevOps Developer

Thomas Berglund

Product Manager at AMRA Medical

Nicklas Weman

Software Architect at AMRA Medical

David Pärsson

AMRA To Share Baseline Results from ACCESS-ESLD @ AASLD’s The Liver Meeting 2024 If you’re in San Diego this week for the 75th annual AASLD’s The Liver Meeting (TLM), make sure to check out AMRA’s poster (#4137) today November 18 @ 1PM - where our own Dr. Mikael Forsgren will be sharing baseline results from the important ACCESS-ESLD study! ACCESS-ESLD is a Swedish multi-center study led by Linköping University that includes 150 adult patients with liver cirrhosis undergoing hepatocellular carcinoma surveillance. Over a duration of 2 years, patients will be assessed every 6 months with a comprehensive clinical examination and a whole-body MRI examination. The study shows that adverse muscle composition, the combination of low muscle volume and high muscle fat, is a highly prevalent phenotype (20%) in this patient group. This population presented with higher frailty, poorer physical performance, and worse health status regardless of muscle volume, underscoring the importance of considering muscle fat alongside muscle volume to identify vulnerable sarcopenic patient groups within liver disease. The study investigators hope that the findings of ACCESS-ESLD will continue the shift in management of liver disease towards employing more of a preemptive approach, by developing ways to monitor disease progression and severity while also identifying patients at risk for major adverse events or mortality. AMRA’s significant involvement in a hallmark study in the liver disease space such as this one embodies the company’s commitment to advancing both research and clinical care. Come find us at TLM 2024 to learn more about AMRA Medical and how the use of MRI-based body composition analysis is advancing disease research in liver disease and beyond! #AMRAMedical #TLM24 #TLMdX #LiU #ACCESSESLD #liverdisease #cirrhosis #clinicaltrials #precisionmedicine #MRI

AMRA is Leveling Up Liver Disease Research at AASLD’s The Liver Meeting 2024! AMRA Medical is excited to announce that we are once again contributing to the conversation at the 75th annual AASLD The Liver Meeting (TLM) in San Diego this month! This year’s TLM, which runs from November 15th-19th and marks AMRA’s seventh consecutive appearance at the global conference, will gather the hepatology field’s top researchers, providers, and companies to facilitate knowledge transfer across academia, industry, and the clinic. The goal of TLM is to showcase the latest in liver disease research and ultimately move forward the efforts in making liver disease less of a burden for patients. AMRA is proud to be a major contributor to liver disease research efforts and a household name at TLM, staying true to our mission of pioneering insights in metabolic health and beyond. If you’re attending this year’s TLM, make sure to come connect with us! Our own Mikael Forsgren , PhD will be presenting at the conference, sharing baseline results from the important ACCESS-ESLD study on Monday, November 18th at the poster symposium 1-2 PM. AMRA’s Olof Dahlqvist Leinhard , PhD and Leanna Kellerman , RN, BSN, MBA will also be in attendance, ready to connect and answer any questions you may have about how AMRA can transform your liver disease research efforts. If you can’t make AASLD’s 75th TLM but would like to get in touch with AMRA, reach out to us at info@amramedical.com to learn more. We hope to see you in San Diego! #AMRAMedical #TLM24 #TLMdX #LiU #ACCESSESLD #liverdisease #cirrhosis #clinicaltrials #precisionmedicine #MRI

Attending Obesity Week? Meet the AMRA team in person! We’re here and excited to connect with you. Reach out to us at info@amramedical.com to schedule a meet-up. 📄 Dive into our latest research! Check out the abstract presented at Obesity Week here: https://shorturl.at/qe0NO These are results from a recent study that unraveled hidden weight gain, adverse muscle composition, and cardiometabolic risk increases in antidepressant users. The study, which is part of the CoMorMent Initiative, was recently published in Obesity as an “Editor’s Choice” piece. If you missed our previous article about it, view it here: https://shorturl.at/WJcR0 #AMRAMedical #OW2024 #goteamAMRA #bodycomposition #musclecomposition #obesity #weightloss #GLP1 #clinicaltrials #CoMorMent

AMRA is Gearing Up For ObesityWeek® 2024! We’re excited to see you all in San Antonio, TX for The Obesity Society’s 2024 edition of ObesityWeek®, which is set to kick off this Sunday! ObesityWeek®, which runs until November 6, is the global home of the latest developments in evidence-based obesity science. The event brings together researchers, clinicians, drug developers, and policy experts to help move the obesity field forward, and AMRA is proud to share our latest findings in the field at this important event. AMRA researchers will be presenting results from a recent study that unraveled hidden weight gain, adverse muscle composition, and cardiometabolic risk increases in antidepressant users. The study, which is part of the CoMorMent Initiative, was recently published in Obesity as an “Editor’s Choice” piece. You can learn more about the study by finding our poster no. 133 titled ‘Hidden Weight Gain, Adverse Muscle Composition and Cardiometabolic Risks in Antidepressant Users’ during the session on November 3rd at 07.30 CDT. Come connect with us at OW2024, or reach out to us at info@amramedical.com to learn more. We hope to see you in the Lone Star State next week! #AMRAMedical #OW2024 #goteamAMRA #bodycomposition #musclecomposition #obesity #weightloss #GLP1 #clinicaltrials #CoMorMent

We are looking for a passionate person to join our DevOps team! As a software developer at AMRA, you will work in a small team, living the DevOps philosophy. The responsibilities include everything from defining requirements for new features, design, implementation and testing, to deployment, operation and maintenance. Read more about this opportunity here: https://lnkd.in/gC2c734U #SoftwareDeveloper #TechCareers #AMRAMedical #JobOpportunity #ClinicalTrials #MRI #PrecisionMedicine

New AMRA Medical research in Muscle & Nerve demonstrates the utility of MRI-based biomarkers in inflammatory myopathies. The recent study details the use of fat-referenced volumetric muscle composition measurements as reliable biomarkers of disease progression and treatment response in sporadic inclusion body myositis (sIBM), building upon AMRA’s increasing expertise in the neuromuscular disease space. AMRA’s success in demonstrating the utility of these fat-referenced MRI-based muscle composition biomarkers in Facioscapulohumeral Muscular Dystrophy (FSHD) and now in inflammatory myopathies such as sIBM is a testament to the rigor and reproducibility of these composite measurements, transcending various pathologies and allowing for the wide applicability of this biomarker suite to neuromuscular disease research in general. Read more about this study and how AMRA is committed to helping pioneer the next wave of neuromuscular disease trials: https://lnkd.in/gr9hmMgY #AMRAMedical #sIBM #FSHD #MRI #bodycomposition #musclecomposition #NeuromuscularDisorders #NeuromuscularDiseases #RareDiseases #ClinicalResearch #ClinicalTrials

📣 AMRA® Profiler 4 pilot study demonstrates feasible assessment of muscle composition in liver transplant candidates 🔬 The FDA 510(k) cleared and newly MDR-certified, next-generation AMRA® Profiler 4 device, a unique approach for quantifying fat and muscles, was evaluated in the study to be helpful in liver disease research, representing a crucial step forward for the use of muscle composition assessments in the field. AMRA® MAsS Scan, powered by AMRA® Profiler 4 is a unique, specialized rapid neck-to-knee MRI protocol and automated image analysis technique that provides volumetric assessments of skeletal muscles and muscle fat infiltration. Learn more about the study and AMRA® Profiler 4 here: https://lnkd.in/dCYHNK-q #AMRAMedical #AMRAProfiler #MAsSScan #MRI #Bodycomposition #Musclecomposition #precisionmedicine #Medicaldevice #Medicalresearch #Liverdisease

🔬 New AMRA Medical study published in Obesity links antidepressant use with poor muscle health and increased cardiometabolic risk. The study – part of the CoMorMent initiative – provides new evidence for body composition measurements as an important tool for examining adverse treatment effects associated with the use of antidepressants. Read more about this study here: https://lnkd.in/dRbRA3kT #ObesityJournal #CoMorMent #AMRAMedical #mentalhealth #bodycomposition #MuscleHealth #muscle #fat #MRI #SSRIs #ClinicalResearch #pharma

🔬 AMRA Publishes Review Article in Renowned Cardiovascular Journal, “Circulation” 🫀 We are proud to share that a recent review primer - co-authored by our very own Jennifer Linge , PhD - was published in Circulation! The article explores the complex relationship between GLP-1-based therapies and muscle health, particularly in the context of using the drugs for weight reduction. As weight loss treatments reach new heights, understanding their impact on muscle composition & quality is crucial. The recently published primer summarizes contemporary evidence, generated by AMRA’s gold-standard MRI-based analysis technology, that indicates muscle composition changes associated with GLP-1-based therapies appear to be adaptive. These findings and more outlined by the authors aim to help ensure that the obesity field develops products with safety and the impact on vulnerable populations in mind. 📖 Read the full release announcing this publication here: https://lnkd.in/dSbYVSNv 📌 Follow us to learn more about AMRA Medical and how the use of MRI-based fat distribution and muscle composition analysis is advancing disease research in metabolic diseases and beyond. #HealthcareInnovation #MuscleHealth #GLP1s #PrecisionMedicine #Obesity #AMRAMedical #ClinicalResearch #BodyComposition #pharma #Circulation #MetabolicDisease #Sarcopenia #Type2Diabetes

AMRA is at WMS 2024! 🌍 From October 8th-12th, the World Muscle Society will be holding its 29th Annual Congress in Prague, Czechia - and you can catch AMRA Medical presenting their latest research findings in Facioscapulohumeral muscular dystrophy (FSHD). The poster presents baseline data from the largest natural history study in FSHD using whole-body MRI - the CTRN FSHD France study - analyzed with the AMRAⓇ Researcher platform to validate new MRI-based outcome measures, define minimal clinically important changes, and establish FSHD characteristics useful for determining clinical trial eligibility criteria. Studies such as this one aim to accelerate FSHD drug development by fulfilling an increasing need for extensive natural history studies that describe disease characteristics and progression using methods that later will be used as clinical trial endpoints. AMRA is proud to be a part of WMS 2024, an important consortium working to make the world a better place for patients of NMDs, and is excited to share with the community how our MRI-based biomarkers are transforming drug trials in FSHD. Come connect with us at the congress, or reach out to us at info@amramedical.com to learn more! #AMRAMedical #FSHD #goteamAMRA #bodycomposition #musclecomposition #NeuromuscularDisorders #ScientificSociety #NeuromuscularDiseases #RareDiseases #Physiology #WMS2024

Metric
Company Name	AMRA Medical	Gesund.ai
Symbol
MSH ID	COM:AMRAMEDICAL	AI:GESUND
Market	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services
Industry	Medical Imaging	Healthcare Technology
Country	SE	DE
Stage
Employee Count
Website	amramedical.com	gesund.ai
LinkedIn	amramedical	gesund-ai
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	1.73K	176
Web Traffic Growth	-0.27	-0.50
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

AMRA

COM:AMRAMEDICAL

AMRA Medical

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue